GlassScriptPhysician profile
Lakshmikanth Katragadda
NPI 1336303940
$11,572.67
in general payments reported to CMS, 2019-2025
71 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $587 · 2021: $1,949 · 2022: $1,285 · 2023: $1,829 · 2024: $1,644 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,039 · Education: $136 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,038.97 |
| Education | $136.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,804.95 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Genzyme Corporation | $743.59 | 2019-2025 | |
| Pfizer INC. | $598.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $596.59 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $512.45 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $474.14 | 2020-2025 | Xpovio |
| Seagen INC. | $446.59 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Welch Allyn | $432.31 | 2021 | |
| Eisai INC. | $396.69 | 2019-2025 | |
| Celgene Corporation | $355.75 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $293.18 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Glaxosmithkline, LLC. | $291.58 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $276.98 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $270.12 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pharmacyclics LLC, An Abbvie Company | $266.89 | 2019-2023 | Epkinly, Imbruvica |
Show all 70 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmikanth Katragadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.